Used in Alzheimers Disease

Triflusal, a known antiplatelet agent used in the treatment of thromboembolic disorders, is currently being evaluated for use in Alzheimer disease. It has been shown to inhibit the activation of the mediators of neuroinflammation. 

Shepardson NE et al (2011) Cholesterol level and statin use in Alzheimer disease I. Review of epidemiological and preclinical studies. Arch Neurol 68 1385-1392... 

Zanetti O, Frisoni GB, De Leo D, Dello Buono M, Bianchetti A and Trabucchi M (1995). Reality orientation therapy in Alzheimer disease useful or not A controlled study. Alzheimer Disease and Associated Disorders, 9, 132-138. 

Spencer CM, Noble S, Rivastigmine—A Review of its use in Alzheimer s disease. Drugs Aging y33 -, 1998. 

Rivastigmine, Donepezil, Tacrine etc. (used in Alzheimer s disease). ... 

This leaves the method of using the compound for the enhancement of cognition in Alzheimer disease. As we discussed before, a conception date can be the date of... 

Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR. 1998. Efficacy of xanomeline in alzheimer disease Cognitive improvement measured using the computerized neuropsychological test battery (CNTB). Alzheimer Dis Assoc Disord 12 304-312. 

Metrifonate has been used for the treatment of schistosomiasis for almost 40 years. Its identification as a cholinesterase inhibitor, together with recognition of the cholinergic deficit in Alzheimer s disease, has led to its use in Alzheimer s disease. 

The pharmacology and pharmacokinetics of metrifonate and experience with its use in Alzheimer s disease have been reviewed (1). 

Physostigmine, under investigation for potential use in Alzheimer s disease, is possibly formed from Nfe-methyltryptamine through a radical mechanism involving C-3 methylation and concomitant C-2 cycli-zation, followed by N -methylation (Fig. 34). 

Acetyl-L-carnitine has been shown to cause a slowdown in the decline of cognitive measures in a number of studies conducted on subjects with mild Alzheimer s disease or mild cognitive impairment. However, one of the most recent double-blind trials conducted on its use in Alzheimer s showed very little difference between acetyl-L-carnitine and placebo. A recent metaanalysis of all the double-blind controlled clinical trials of acetyl-L-carnitine concentrated on patients who had mild cognitive impairment or mild Alzheimer s, and found that of 21 studies conducted, 17 showed that it had a positive effect on patients this however included some unpublished trials. 

Elderly people need to be treated with caution because of their greater susceptibility to the cardiovascular effects of the acetylcholinesterase inhibitors this is particularly relevant to their use in Alzheimer s disease. 

---